Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AmerisourceBergen

Amneal Pharmaceuticals

Cardinal Health

Endo International

McKesson

Mallinckrodt PLC

Teva Pharmaceutical

Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources.

Shares of opioid makers and distributors drop on criminal probe

Blue Apron

Beyond Meat

Rite Aid

Shopify

Spotify

Tilray Brands

These stocks to sell will likely face pain in 2020 as these equities face worsening conditions and increasing financial and market pressure.

7 Unsteady Stocks Investors Should Consider Selling Before 2020

Eli Lilly

Which stock wins in a head-to-head matchup between these two healthcare giants?

Better Buy: Johnson & Johnson vs. Eli Lilly

AstraZeneca

These big drugmakers' CEOs have delivered strong total returns and enjoy widespread employee approval.

Like to Bet On the Jockey? Consider These 2 Big Pharma Stocks

More than 1,350 Australian women won a seven-year-old class action lawsuit on Thursday against Johnson & Johnson (J&J) for misleading patients and surgeons about the risks of the pharmaceutical giant's pelvic mesh implants.

Johnson & Johnson loses pelvic mesh class action in Australia

The boost Johnson and Johnson gets from a reduced payout in Oklahoma will prove temporary as JNJ faces many more judgments.

Reduced Opioid Payout Is No Reason to Buy Johnson and Johnson Stock

American Electric Power Company

Chevron

Dollar General

Disney

General Mills

Altria

Papa John's

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

With the U.S. and China moving toward a trade dispute resolution, the markets have responded with incredibly bullish fervor.

9 Tantalizing Dividend Stocks for 2020

NextEra Energy

Philip Morris

Seeking out specific types of investments could have your portfolio thriving when the next recession strikes.

3 Easy Ways You Can Make Money During a Recession

An Oklahoma judge on Friday said Johnson & Johnson  must pay that state $465 million for fueling the opioid epidemic through the deceptive marketing of painkillers, down from his original award of $572 million.

Oklahoma judge reduces Johnson & Johnson opioid payout to $465 million

An Oklahoma judge on Friday reduced the penalty Johnson & Johnson must pay over litigation stemming from the opioid epidemic.

Johnson & Johnson stock climbs as judge reduces opioid penalty to $465 million

An Oklahoma judge on Friday said Johnson & Johnson  only needs to pay $465 million of the $572 million he previously concluded it owed the state for fueling the opioid epidemic through deceptive painkiller marketing.

Oklahoma judge reduces Johnson & Johnson payout in opioid case to $465 million

AbbVie

Bristol-Myers

Merck

Pfizer

Drug stocks have been out of favor due to regulatory concerns. Nevertheless, several top-tier stock experts and contributors to MoneyShow.com see select opportunities for long-term value investors to consider buying large cap pharmaceutical names.

Out-of-Favor Drugs Stocks May be the Right Medicine For Your Portfolio

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Why Is Johnson & Johnson (JNJ) Down 2.9% Since Last Earnings Report?

Johnson & Johnson's Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows.

J&J blockbuster loses ground to biosimilars despite Quebec court ruling

Boeing

Cisco Systems

Goldman Sachs

Home Depot

Intel

JPMorgan Chase & Co

Travelers

Walgreens

Dividend stocks can be an excellent source of reliable returns during unpredictable periods in the market.

12 Dow Stocks With At Least 2% Dividend Yields

Johnson&Johnson stock could be just what the doctor ordered for long-term portfolios if the stock market becomes more volatile. 
The post Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?

Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?

J&J’s (NYSE:JNJ) stock was weaker in the quarter as litigation uncertainty was more of a focus than the company’s strong business fundamentals.

Yacktman Focused Fund Comments on Johnson & Johnson

Caterpillar

McDonald's

UnitedHealth Group

Exxon Mobil

When investors hear that the stock market just hit a new all-time high, it’s probably fairly easy to assume that this means almost all the individual stocks are probably at all-time highs as well.

As the Dow Hits All-Time High, Over Half of Dow Stocks Keep Disappointing Investors

News for Johnson & Johnson Stock (JNJ)